Merve Keskinkilic | Medical Oncology | Best Researcher Award

Posted on by ScienceFather

Dr. Merve Keskinkilic | Medical Oncology | Best Researcher Award

Medical Oncologist, Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital Turkey

Merve Keskinkılıç is a dedicated Medical Oncologist at Burdur State Hospital with a strong academic background in Internal Medicine and Medical Oncology. She earned her M.D. from Dokuz Eylul University Faculty of Medicine and completed her Medical Oncology Fellowship at the same institution. Dr. Keskinkılıç has extensive clinical experience, having served as a Research Fellow at Emory University, USA. Fluent in English (C1 Advanced) and proficient in German (Elementary), she actively participates in international oncology research. Her expertise includes clinical trials, cancer treatment strategies, and translational oncology research, contributing significantly to advancements in the field.

Publication Profile

Scopus

Scholar

🎓 Education

Dr. Keskinkılıç completed her high school education at Balıkesir Science High School (2004-2008) before pursuing medicine at Dokuz Eylul University (2008-2014). She participated in an Oncology Exchange Program at Mansoura University, Egypt (2010). She later obtained an Associate Degree in Healthcare Management from Anadolu University (2014-2017). Her residency in Internal Medicine was completed at Celal Bayar University (2015-2016) and Dokuz Eylul University (2016-2019). She pursued a Medical Oncology Fellowship at Dokuz Eylul University (2019-2024) and is currently undertaking a PhD in Basic Oncology at Dokuz Eylul University Oncology Institute (since 2022). She also worked as a Research Fellow at Emory University, USA (2023).

💼 Experience

Dr. Keskinkılıç began her career as a General Practitioner at Balıkesir Susurluk State Hospital (2014-2015) before becoming a Research Assistant in Internal Medicine at Celal Bayar University (2015-2016) and later at Dokuz Eylul University (2016-2019). She served as a Specialist Doctor at Bitlis Mutki State Hospital (2019) and as a Fellow in Medical Oncology at Dokuz Eylul University (2019-2024). Currently, she is a Medical Oncologist at Burdur Public Hospital (2024-2025) and will join Izmir Democracy University Buca Seyfi Demirsoy Training and Research Hospital in 2025.

🏆 Awards & Honors

Dr. Keskinkılıç holds several prestigious certifications, including the Turkish Board of Internal Medicine Certificate (2018), Experimental Animal Use Certificate (2019), Oncology Clinical Research Training Certificate (2020), and ESMO Board of Examination Certificate (2023). She has also completed Good Clinical Practices (ICU) and Clinical Research Training and has received certifications in Research Ethics and Clinical Trials. Her contributions to oncology research and education have been recognized through multiple national and international accolades.

🔬 Research Focus

Dr. Keskinkılıç specializes in clinical oncology research, focusing on urothelial, bladder, gastric, prostate, and lung cancers. She is actively involved in multiple clinical trials, serving as a Sub-Investigator in research projects such as THOR (Urothelial Cancer), Niagara (Bladder Cancer), MK3475-859 (Gastric Cancer), Regeneron (Non-Small Cell Lung Cancer), and Radiant 20510 (Prostate Cancer). Her work emphasizes innovative treatment strategies, immunotherapy, and targeted cancer therapies, contributing to the development of advanced oncological treatments. Her internal medicine dissertation evaluated CMV DNA Antigenemia in Allogeneic Bone Marrow Transplant Patients.

Publication Top Notes

  • Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
    • Authors: C. Karacin, B. Oksuzoglu, A. Demirci, M. Keskinkılıç, et al.
    • Journal: BMC Cancer, 2023
    • Citations: 20

 

  • Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    • Authors: S. Kahraman, E. Erul, M. Seyyar, O. Gumusay, et al.
    • Journal: Future Oncology, 2023
    • Citations: 13

 

  • Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: a multicenter study
    • Authors: H. Ç. Yıldırım, E. Mutlu, E. Chalabiyev, M. Özen, et al.
    • Journal: The Breast, 2022
    • Citations: 13

 

  • The effect of low HER2 expression on treatment outcomes in metastatic hormone receptor-positive breast cancer patients treated with a combination of a CDK4/6 inhibitor and…
    • Authors: E. C. Yildirim, E. Atag, E. Coban, et al.
    • Journal: The Breast, 2023
    • Citations: 12

 

  • Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia
    • Authors: H. C. Yildirim, C. Kapar, B. Koksal, et al.
    • Journal: Journal of Chemotherapy, 2024
    • Citations: 4

 

  • The prognostic indicator in breast cancer treated with CDK4/6 inhibitors: the prognostic nutritional index
    • Authors: M. Keskinkilic, H. S. Semiz, G. Polat, et al.
    • Journal: Future Oncology, 2023
    • Citations: 4

 

  • Antibody-Drug Conjugates in Triple Negative Breast Cancer
    • Authors: M. Keskinkilic, R. Sacks
    • Journal: Clinical Breast Cancer, 2024
    • Citations: 3

 

  • 194P Increased blood creatinine level due to CDK 4/6 inhibitor treatments: single center experience
    • Authors: M. Keskinkılıç, H. S. Semiz, T. Yavuzsen, A. Karaoglu
    • Journal: Annals of Oncology, 2022
    • Citations: 3

 

  • The prognostic nutritional index (PNI): A new biomarker for determining prognosis in metastatic castration-sensitive prostate carcinoma
    • Authors: H. I. Ellez, M. Keskinkilic, et al.
    • Journal: Journal of Clinical Medicine, 2023
    • Citations: 11

 

  • The role of immune checkpoint inhibition in triple-negative breast cancer
    • Authors: K. Tarekegn, M. Keskinkilic, T. J. Kristoff, S. T. Evans, K. Kalinsky
    • Journal: Expert Review of Anticancer Therapy, 2023
    • Citations: 10

 

  • The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer
    • Authors: M. Hizal, B. Bilgin, N. Paksoy, et al.
    • Journal: Journal of Cancer Research and Clinical Oncology, 2023
    • Citations: 5

 

  • CD47 (‘don’t eat me’ signal) expression levels and its relationship with clinicopathologic features in early‐stage prostate carcinoma
    • Authors: H. S. Semiz, Ü. Küçük, E. Kısa, M. Keskinkılıç, et al.
    • Journal: The Prostate, 2022
    • Citations: 5

 

  • A severe case of levothyroxine intoxication successfully treated in intensive care unit
    • Authors: Y. Savran, T. Mengi, M. Keskinkilic
    • Journal: Journal of Acute Disease, 2018
    • Citations: 11

 

 

Somnath Paul | Cancer Immunotherapy | Best Researcher Award

Posted on by ScienceFather

Dr. Somnath Paul | Cancer Immunotherapy | Best Researcher Award

Staff Scientist, Washington University United States

Somnath Paul, Ph.D., is a Staff Scientist in the Department of Pathology and Immunology at Washington University in St. Louis, MO. With a robust academic and research career, he specializes in molecular genetics, epigenetics, and immunology. Over the years, Dr. Paul has contributed significantly to cancer research, developing new strategies for tumor profiling and immunotherapy. He has worked at prestigious institutions like the University of Texas MD Anderson Cancer Center and CSIR-Indian Institute of Chemical Biology, publishing several key research articles.

Profile

Scopus

Scholar

🎓 Education

Dr. Paul earned his Ph.D. in Molecular and Human Genetics from Jadavpur University, India (2016), after completing a Master’s in Genetics at the University of Calcutta (2008). He began his academic journey with a Bachelor’s in Physiology from Presidency College, University of Calcutta (2006). His educational foundation laid the groundwork for his research focus on epigenetics, immunology, and cancer biology.

💼 Experience

Dr. Paul’s professional career spans prestigious institutions, including Washington University (2024–Present), University of Texas MD Anderson Cancer Center (2020–2024), and CSIR-Indian Institute of Chemical Biology (2009–2016). His work focuses on immunotherapy, monoclonal antibody production, and the genetic regulation of cancer. He has been a postdoctoral fellow, research scientist, and project assistant, contributing to several groundbreaking research projects in molecular biology, toxicology, and immunology.

🏆 Awards and Honors

Dr. Paul has received notable accolades, such as the prestigious NIH-funded research project on INO80 chromatin remodeling. He was also honored with research excellence awards, including one from GEU, DDN in 2015, and the Early Career Research Award from SERB (2017). Additionally, he received travel grants from DST (2012) and presented a best paper at TriboIndia-2023 Conference.

🔬 Research Focus

Dr. Paul’s research is primarily centered on understanding tumor progression through circulatory tumor cell profiling, tumor remission and relapse monitoring, and novel monoclonal antibody development for immunotherapy. His work includes studying the infection dynamics of herpes viruses, epigenetic mechanisms of cancer, and identifying biomarkers for early disease detection. He aims to enhance therapeutic strategies through innovative platforms and experimental models.

🏆 Conclusion

Dr. Somnath Paul is a strong contender for the Best Researcher Award due to his robust academic and research portfolio, innovative contributions, and extensive publication record. Addressing the identified areas for improvement could further bolster his candidacy for this and similar accolades in the future.

Publication

  1. Arsenic exposure through drinking water increases the risk of liver and cardiovascular diseases in the population of West Bengal, India
    Year: 2012
    Authors: N Das, S Paul, D Chatterjee, N Banerjee, NS Majumder, N Sarma, TJ Sau, …
    Citations: 150

 

  1. Functional compensation of glutathione S-transferase M1 (GSTM1) null by another GST superfamily member, GSTM2
    Year: 2013
    Authors: P Bhattacharjee, S Paul, M Banerjee, D Patra, P Banerjee, N Ghoshal, …
    Citations: 104

 

  1. Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex
    Year: 2017
    Authors: P Sen, J Luo, A Hada, SG Hailu, ML Dechassa, J Persinger, S Brahma, …
    Citations: 99

 

  1. The Arp8 and Arp4 module acts as a DNA sensor controlling INO80 chromatin remodeling
    Year: 2018
    Authors: S Brahma, M Ngubo, S Paul, M Udugama, B Bartholomew
    Citations: 81

 

  1. Arsenic-induced toxicity and carcinogenicity: a two-wave cross-sectional study in arsenicosis individuals in West Bengal, India
    Year: 2012
    Authors: S Paul, N Das, P Bhattacharjee, M Banerjee, JK Das, N Sarma, A Sarkar, …
    Citations: 78

 

  1. Arsenic-induced promoter hypomethylation and over-expression of ERCC2 reduces DNA repair capacity in humans by non-disjunction of the ERCC2/Cdk7 complex
    Year: 2014
    Authors: S Paul, N Banerjee, A Chatterjee, TJ Sau, JK Das, PK Mishra, …
    Citations: 65

 

  1. Recent advances in arsenic research: significance of differential susceptibility and sustainable strategies for mitigation
    Year: 2020
    Authors: T Sanyal, P Bhattacharjee, S Paul, P Bhattacherjee
    Citations: 62

 

  1. Epimutagenesis: A prospective mechanism to remediate arsenic-induced toxicity
    Year: 2015
    Authors: S Paul, AK Giri
    Citations: 52

 

  1. Risk of Occupational exposure to Asbestos, Silicon and Arsenic on Pulmonary Disorders: Understanding the Genetic-Epigenetic Interplay and Future Prospects.
    Year: 2016
    Authors: P Bhattacharjee, S Paul, P Bhattacharjee
    Citations: 47

 

  1. Epigenetic Modifications of DAPK and p16 Genes Contribute to Arsenic-Induced Skin Lesions and Non-Dermatological Health Effects
    Year: 2013
    Authors: N Banerjee, S Paul, TJ Sau, JK Das, A Bandyopadhyay, AK Giri
    Citations: 44

 

 

Jessica Abene| Oncology| Best Researcher Award

Posted on by ScienceFather

Ms. Jessica Abene| Oncology| Best Researcher Award

Ms. University of Pennsylvania,  United States

Jessica Abene is a dedicated nursing professional with a passion for advancing healthcare through evidence-based research. She earned her Bachelor of Nursing Science (BSN) from the University of Pennsylvania in 2023 and is currently pursuing a Master’s in Statistics and Data Science, as well as a PhD. Jessica is deeply engaged in research focused on improving patient care, particularly in oncology and eating disorders. She is an author of several publications, including systematic reviews on chemotherapy toxicities, food insecurity, and binge eating. Her expertise extends to clinical trials and the development of innovative healthcare solutions, such as a smart swaddle for infants with neonatal abstinence syndrome. Jessica is committed to improving patient quality of life through her work as a graduate research assistant and peer reviewer.

Profile

Scopus

🎓 Education

University of Pennsylvania Bachelor of Nursing Science (BSN), 2023. Master of Statistics and Data Science, In Process. Doctor of Philosophy, In Process

💼 Experience

Graduate Research Assistant, University of Pennsylvania, 2021-Present Jessica leads research on diet interventions to alleviate chemotherapy toxicities, coordinates data for clinical trials, and manages a systematic review on food insecurity and binge eating. Peer Reviewer, European Journal of Oncology Nursing, 2024-Present Evaluates submissions for scientific rigor, providing feedback to improve clarity and validity. Penn Nursing Innovation Accelerator Awardee, 2022 Led a team to develop a smart swaddle for infants with neonatal abstinence syndrome, offering comfort and distress relief.

🏆 Awards & Honors

Best Review Paper, International Journal of Eating Disorders (2023) Recognized for outstanding scholarly work as an early career scholar. Rita and Alex Hillman Foundation Pilot Award ($5,000) Awarded for innovative healthcare research. Doctoral Student Organization Research Grant ($325) Provided funding to support academic research. Penn Nursing Innovation Accelerator Awardee ($2,500) Awarded for leading an innovation team developing a smart swaddle system. Eastern Nursing Research Society Annual Conference Abstract Presentation (2023) Presented impactful research findings.

🔬 Research Focus

Jessica’s research aims to improve patient outcomes through evidence-based interventions. She is particularly focused on the impact of diet on chemotherapy toxicities and quality of life, as well as the relationship between food insecurity and binge eating disorders. Additionally, she coordinates clinical trials and studies exploring the effects of lymphedema and fibrosis treatment. Her innovative work includes developing a smart swaddle system for infants with neonatal abstinence syndrome (NAS). Jessica’s research seeks to create practical solutions for complex health challenges and contribute to enhancing patient care in diverse clinical settings.

🏆Conclusion 

Jessica Abene’s combination of rigorous academic training, innovative research, and leadership in healthcare makes her a standout candidate for the Best Researcher Award. Her systematic reviews, dedication to improving patient quality of life, and groundbreaking work in the intersection of healthcare and technology reflect her potential to make significant contributions to the nursing field. Continuing to expand her research network and engaging more broadly with the community will further enhance her already impressive career trajectory.

Publication

  • Dietary Interventions for Alleviating Chemotherapy Toxicities in Patients with Cancer: A Systematic Review
    Year: 2024
    Authors: Abene, J. & Deng, J.
    Status: In process

 

  • Diet as an Adjunct Therapy in Reducing Chemotherapy Toxicities and Improving Patients’ Quality of Life: A Systematic Review and Meta-Analysis
    Year: 2024
    Authors: Abene, J., Tyburski, S., Kral, T. V. E., Quinn, R., & Deng, J.
    Journal: Nutrition and Cancer, 1–19
    DOI: 10.1080/01635581.2024.2437833

 

  • Food Insecurity and Binge Eating: A Systematic Review and Meta-Analysis
    Year: 2023
    Authors: Abene, J. A., Tong, J., Minuk, J., Lindenfeldar, G., Chen, Y., & Chao, A. M.
    Journal: The International Journal of Eating Disorders, 56(7), 1301–1322

 

  • Binge Eating Disorder and Eating Self-Efficacy in Adults Seeking Bariatric Surgery
    Year: 2022
    Authors: Chao, A. M., Abene, J., Allison, K. C., Pearl, R. L., Wadden, T. A., Williams, N. N., & Tronieri, J. S.
    Journal: Clinical Obesity, e12531
    DOI: 10.1111/cob.12531

 

  • The Importance of Student Nursing and Engineering Collaborations
    Year: 2022 (May 20)
    Authors: Leary, M., Abene, J.
    Journal: American Nurse

 

Di Zhu| Immuno-oncology| Best Researcher Award

Posted on by ScienceFather

Mr. Di Zhu| Immuno-oncology| Best Researcher Award

Professor at Fudan University,  China

Di Zhu is a Professor in the Department of Pharmacology at Fudan University, specializing in immuno-oncology and cancer research. Born on October 13, 1983, he holds a Ph.D. in Biochemistry and Molecular Biology. With over 8 years of academic experience, he has pioneered groundbreaking therapies targeting colorectal cancer. Recognized globally for his contributions to cancer immunotherapy, he combines innovative research with clinical applications to improve patient outcomes.

Profile

Scholar

Education 🎓

Ph.D. in Biochemistry & Molecular Biology (2005–2010), Shanghai Institute of Biochemistry and Cell Biology, CAS. Postdoctoral Fellow (2011–2015), Dana-Farber Cancer Institute, Harvard University. Undergraduate studies at Shandong University, earning accolades like the National Sci. & Tech. Challenge Cup (2004).

Experience 💼

Researcher: Fudan University, School of Basic Medical Sciences (2021–Present). Researcher: Minhang & Zhongshan Hospitals, Fudan University (2017–Present). Researcher: Fudan University, School of Pharmacy (2016–2021). Led 12 projects, supervised 16 research scholars, and organized 5 workshops globally.

Awards and Honors 🏅

Gold Medal: Global Life & Health Technology Concept Validation (2024). Excellence Award: Hai Ju Ying Cai Global Innovation (2024). Outstanding Young Scientist: Shanghai Society of Biotechnology (2022). 1000 Talent Young Award: CPC Central Committee (2016). Multiple national and international recognitions for cancer research.

Research Focus 🔬

Therapies: Pioneered BCL9/β-catenin inhibitors for colorectal cancer. Immunotherapy: Enhanced T-cell responses and reduced immune resistance. Innovative Molecules: Developed selective inhibitors for challenging pathways. Publications: Authored impactful research in top journals, advancing cancer treatment.

Conclusion

Dr. Di Zhu exemplifies the qualities of a world-class researcher. His groundbreaking contributions to cancer therapy, robust academic output, and numerous accolades strongly support his nomination for the Best Researcher Award, affirming his leadership and innovation in the field of pharmacology and immuno-oncology.

Publication

 

  • Clinical cancer immunotherapy: Current progress and prospects
    Authors: C Liu, M Yang, D Zhang, M Chen, D Zhu
    Journal: Frontiers in Immunology 13, 961805
    Citations: 140 (2022)

 

  • Wnt signaling pathway in cancer immunotherapy
    Authors: Y Zhou, J Xu, H Luo, X Meng, M Chen, D Zhu
    Journal: Cancer Letters 525, 84-96
    Citations: 125 (2022)

 

  • IFNα potentiates anti–PD-1 efficacy by remodeling glucose metabolism in the hepatocellular carcinoma microenvironment
    Authors: B Hu et al., including D Zhu
    Journal: Cancer Discovery 12 (7), 1718-1741
    Citations: 123 (2022)

 

  • The Cyclophilin A–CD147 complex promotes the proliferation and homing of multiple myeloma cells
    Authors: DI Zhu et al.
    Journal: Nature Medicine 21 (6), 572-580
    Citations: 116 (2015)

 

  • Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells
    Authors: M Feng et al., including D Zhu
    Journal: Science Advances 5 (5), eaau5240
    Citations: 100 (2019)

 

  • Cyclophilin A and CD147: Novel therapeutic targets for the treatment of COVID-19
    Authors: C Liu, A von Brunn, D Zhu
    Journal: Medicine in Drug Discovery 7, 100056
    Citations: 91 (2020)

 

  • T-cell-based immunotherapy in colorectal cancer
    Authors: M Feng, Z Zhao, M Yang, J Ji, D Zhu
    Journal: Cancer Letters 498, 201-209
    Citations: 67 (2021)

 

  • Targeting the tumor immune microenvironment for cancer therapy in human gastrointestinal malignancies
    Authors: Y Zhang et al., including D Zhu
    Journal: Cancer Letters 458, 123-135
    Citations: 55 (2019)

 

  • Targeting Cyclophilin A and CD147 to Inhibit Replication of SARS-CoV-2 and SARS-CoV-2-Induced Inflammation
    Authors: F Yang et al., including D Zhu
    Journal: Molecular Pharmacology
    Citations: 1 (2023)

 

  • New Approaches Targeting Immuno-oncology and Tumor Microenvironment
    Authors: D Zhu, F He
    Book Chapter: Cancer Treatment: An Interdisciplinary Approach, 63-90
    Citations: 1 (2022)

 

 

 

Muthyam Sowjanya |Cancer | Women Researcher Award

Posted on by ScienceFather

Dr. Muthyam Sowjanya | Cancer | Women Researcher Award

Dr at Vikrama simhapuri university,  India

Sowjanya Muthyam, Ph.D., is a dedicated and highly skilled scientist with 8 years of expertise in immunology, inflammation, molecular biology, cell biology, and biochemistry. Having worked on diverse research projects, including promoting polythene degradation by Spingomonas bacteria and studying bioactive compound production from fungi, Dr. Muthyam seeks a Scientist position to advance industrial, clinical, and translational research.

Profile

Orcid

Education 🎓

Dr. Muthyam holds a Ph.D. in Biotechnology from Andhra University (2014-2019), where her thesis focused on isolating, purifying, and characterizing novel anticancer compounds from Leucas indica flowers. She also completed her M.Sc. in Biotechnology from SRM University (2009-2011), where she studied shell loss in P. monodon and the antiglycation effects of spices. She holds a B.Sc. in Biotechnology, Chemistry, and Computer Applications from Sri Venkateswara University (2006-2009).

Research Experience 💼

Dr. Muthyam’s doctoral research involved isolating and characterizing bioactive compounds from Leucas indica, revealing an anticancer compound that inhibited cancer cell proliferation, particularly in MCF-7 and HeLa cell lines. Her work involved various techniques like column chromatography, UV, TLC, NMR, and apoptosis assays, contributing significantly to cancer treatment strategies. She also collaborated on projects related to bioremediation and bioactive compound production.

Awards 🏆

Dr. Muthyam has received the UGC RGNF fellowship as a Junior Research Fellow (2014-2016) and a Senior Research Fellow (2016-2019). She has also mentored graduate and undergraduate students, supervised research projects, and served as a judge for research poster presentations. Her contributions to the field have earned recognition within the scientific community, particularly for her work on novel anticancer compounds.

Research Focus 🔍

Dr. Muthyam’s primary research focuses on the isolation and characterization of bioactive compounds, with a strong emphasis on anticancer agents. Her work also explores bioremediation strategies, enzyme production, and the application of fungi in industrial processes. Dr. Muthyam is particularly interested in advancing molecular biology, immunology, and biochemistry to develop therapeutics for cancer treatment and environmental sustainability.

Teaching and Mentoring Experience🧑‍🏫

Dr. Muthyam has a solid background in teaching and mentoring, having supervised over 40 graduate students and interns at Andhra University. She has also mentored numerous undergraduate students and evaluated their research poster presentations. Additionally, she is currently serving as a guest faculty member at Vikrama Simhapuri University, where she continues to guide students in research and development.

Conclusion 📝

Dr. Sowjanya Muthyam stands out as a promising researcher with a solid academic foundation, innovative research achievements, and a passion for mentoring the next generation of scientists. Her work, particularly in cancer treatment and bioactive compounds, holds immense potential for future clinical and industrial applications. By focusing on expanding her publication record, collaborations, and public engagement, she can significantly enhance her impact in the scientific community. Dr. Muthyam is a strong candidate for the Women Researcher Award, and her continued contributions will undoubtedly advance the fields of biotechnology and molecular medicine.

Publications 📚

  1. Probiotics Contribution to the Development of Aquaculture: A Review
    • Journal: African Journal of Biological Sciences
    • Date: 2024-07-20
    • Contribution: Sowjanya Muthyam

 

  1. Immobilisation of Aspergillus flavus Strain S4 Spores for Optimal Production and Activity of L-Glutaminase
    • Journal: Chelonian Conservation and Biology
    • Date: 2023-11-11
    • Contribution: Sowjanya Muthyam

 

  1. Incidence of White Feces Syndrome (WFS) and Its Management with Herbal Supplements (Allium sativum and Curcuma longa) by Improving the Growth and Gut Health of Shrimp Litopenaeus vannamei (Boone-1931)
    • Journal: IJFANS International Journal of Food and Nutritional Sciences
    • Date: 2023-11-11
    • Contribution: Sowjanya Muthyam

 

  1. Industrial Applications of Alkaline Protease with Novel Properties from Bacillus cereus Strain S8
    • Date: 2023-11-07
    • Contribution: Sowjanya Muthyam

 

  1. Phytochemical Analysis and Antimicrobial Activity of Muntingia calabura
    • Journal: Journal of Chemical Health Risks
    • Date: 2023-11-07
    • Contribution: Sowjanya Muthyam

 

  1. Characterization of Alkaline Protease from Bacillus cereus Strain S8 by In Silico Approach
    • Journal: Chelonian Conservation and Biology
    • Date: 2023-11-02
    • Contribution: Sowjanya Muthyam

 

  1. In Vitro Antibacterial Activity of Flower Extract of Leucas indica
    • Journal: Journal of Advanced Zoology
    • Date: 2023-11-02
    • Contribution: Sowjanya Muthyam

 

  1. Antiglycation Effect of Chillies and Spices Used in Traditional Indian Cuisine
    • Journal: European Journal of Biomedical and Pharmaceutical Sciences
    • Date: 2023-10-22
    • Contribution: Sowjanya Muthyam

 

  1. Purification, Characterization Studies of L-Glutaminase from Aspergillus flavus Strain S4
    • Journal: Journal of Advanced Zoology
    • Date: 2023-10-01
    • Contribution: Sowjanya Muthyam

 

  1. Probiotics and Their Prolific Role in Shrimp Farming Practices
  • Date: 2022-12-26
  • Contribution: Sowjanya Muthyam

 

Mohammad Khosravi | Immunotherapy | Excellence in Innovation

Posted on by ScienceFather

Assoc Prof Dr. Mohammad Khosravi | Immunotherapy | Excellence in Innovation

Assoc Prof Dr. Shahid Chamran University of Ahvaz Iran

👩‍🔬 A highly skilled immunologist and veterinarian with a Ph.D. from Tehran University, specializing in molecular characterization and immunology techniques. Experienced in cell culture, gene characterization, protein analysis, and chromatography. Proficient in serology techniques, immunization, and animal handling. Skilled in bioinformatics analysis and extensive knowledge of SPSS and Microsoft Office Suite. Adept at teaching fundamental and advanced immunology to both D.V.M. and Ph.D. students. Demonstrated expertise in avian immunology and diagnostic techniques. Accomplished in research and teaching, contributing significantly to the field of immunology and veterinary medicine.🌟

 

Profile

Scopus

 

Education 📚

PhD in Immunology: Tehran University, Tehran, Iran, 2013.Thesis: Molecular characterization of chicken class II transactivator gene.DVM (Doctor of Veterinary Medicine): Shahrekord University, Chaharmahal bakhteyari, Iran, 2007.Thesis: A comparison of ELISA and histopathology for the detection of paratuberculosis in dairy cattle.

Research Experience and Technical Skills 🔬

Cell culture (primary and immortalized cell lines).Stem cell isolation technique.Isolation of leukocyte subsets.Purification of antibody subsets.Gene characterization: PCR, RT-PCR, QRT-PCR, Real Time-PCR, Gene cloning, Bioinformatics analysis.Protein and Oligosaccharide SDS-PAGE.Western blotting.Serology techniques: ELISA, Agglutination, Precipitation, Hemagglutination.Chromatographic techniques: Affinity, Ion-exchange, Gel-filtration.Purification of protein and carbohydrate.Immunization techniques.Animal handling.Extensive experience of SPSS, Microsoft Word, Excel, PowerPoint.Hapten immunization (Preparation of the hyper immune sera against drugs and metals).Synthesis of the metal nanoparticles (Fe, Cu, Au, Zn).Synthesis of the immunomagnetic beads for separation of the microorganisms, cells, drugs, and metals.Synthesis of the latex agglutination beads for detection of the cells, drugs, and metals.

Teaching Experience (2013-2022) 📖

At Shahid Chamran University of Ahvaz, Khuzestan, Iran:

  • Fundamental Immunology for D.V.M students.
  • Advanced Immunology for Ph.D students of bacteriology.
  • Serology Technique for D.V.M students.
  • Avian Immunology for PhD students of poultry hygiene and diseases.
  • Diagnostic Immunology for Ph.D students of clinical pathology.

Publications Top Notes 📝

  1. Title: Quorum quenching probiotics modulated digestive enzymes activity, growth performance, gut microflora, haemato-biochemical parameters and resistance against Vibrio harveyi
    • Authors: R Ghanei-Motlagh, T Mohammadian, D Gharibi, M Khosravi, E Mahmoudi, …
    • Journal: Aquaculture
    • Volume: 531
    • Pages: 735874
    • Year: 2021

 

  1. Title: Quorum Quenching Properties and Probiotic Potentials of Intestinal Associated Bacteria in Asian Sea Bass Lates calcarifer
    • Authors: R Ghanei-Motlagh, T Mohammadian, D Gharibi, S Menanteau-Ledouble, …
    • Journal: Marine drugs
    • Volume: 18
    • Issue: 1
    • Pages: 23
    • Year: 2019

 

  1. Title: Feed supplementation with quorum quenching probiotics with anti-virulence potential improved innate immune responses, antioxidant capacity and disease resistance in Asian …
    • Authors: R Ghanei-Motlagh, D Gharibi, T Mohammadian, M Khosravi, E Mahmoudi, …
    • Journal: Aquaculture
    • Volume: 535
    • Pages: 736345
    • Year: 2021

 

  1. Title: Antibacterial effects of Aloe vera extracts on some human and animal bacterial pathogens
    • Authors: D Gharibi, M Khosravi, Z Hosseini, F Boroun, SK Barzgar, A Forughi Far
    • Journal: Journal of Medical Microbiology and Infectious Diseases
    • Volume: 3
    • Issue: 1
    • Pages: 6-10
    • Year: 2015